LIVIVO - Search results -

Search results

Result 1 - 10 of total 239

Search options

Article ; Online: Prevalence of Lung Cancer Screening in the US, 2022.

Henderson, Louise M / Su, I-Hsuan / Rivera, M Patricia / Pak, Joyce / Chen, Xiaomeng / Reuland, Daniel S / Lund, Jennifer L

JAMA network open

2024 Volume 7, Issue 3, Page(s) e243190

MeSH term(s)	Humans ; Early Detection of Cancer ; Prevalence ; Lung Neoplasms/diagnosis ; Lung Neoplasms/epidemiology
Language	English
Publishing date	2024-03-04
Publishing country	United States
Document type	Journal Article
ISSN	2574-3805
ISSN (online)	2574-3805
DOI	10.1001/jamanetworkopen.2024.3190
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article ; Online: Clinician Perception of Likelihood of Death in the Next Year Is Associated With 1-Year Mortality and Hospice Use Among Older Adults Receiving Home Health Care.

Osakwe, Zainab Toteh / Bollens-Lund, Evan / Wang, Yihan / Ritchie, Christine S / Reckrey, Jennifer M / Ornstein, Katherine A

Journal of palliative medicine

2024 Volume 27, Issue 4, Page(s) 481–486

Abstract: Background: ...

Abstract	Background:
MeSH term(s)	Humans ; Aged ; United States ; Hospice Care ; Hospices ; Prospective Studies ; Medicare ; Home Care Services ; Perception
Language	English
Publishing date	2024-02-12
Publishing country	United States
Document type	Journal Article
ZDB-ID	1427361-5
ISSN	1557-7740 ; 1096-6218
ISSN (online)	1557-7740
ISSN	1096-6218
DOI	10.1089/jpm.2023.0043
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 5440: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: The impact of height and weight on rescreening rates within a population-based breast screening program.

Pirikahu, Sarah / Darcey, Ellie / Lund, Helen / Wylie, Elizabeth / Stone, Jennifer

Cancer medicine

2024 Volume 13, Issue 3, Page(s) e6883

Abstract: Introduction: Women with obesity are at increased risk of post-menopausal breast cancer and less likely to participate in breast screening. This study investigates the impact of asking women their height and weight within a population-based screening ... ...

Abstract	Introduction: Women with obesity are at increased risk of post-menopausal breast cancer and less likely to participate in breast screening. This study investigates the impact of asking women their height and weight within a population-based screening program, and the association of BMI with rescreening status. Methods: Data regarding 666,130 screening events from 318,198 women aged 50-74 attending BreastScreen Western Australia between 2016 and 2021 were used to compare crude and age-standardised rescreening rates over time. Mixed effects logistic regression was used to investigate associations of BMI with rescreening status. Results: Rescreening rates for women screened since 2016 were within 1.8% points from the previous reporting period, stratified by screening round. Increasing BMI was associated with decreased likelihood of returning to breast screening (OR = 0.993, 95% CI: 0.988-0.998; OR = 0.989, 95% CI: 0.984-0.994; OR = 0.985, 95% CI: 0.982-0.987 for women screening for the first, second and third+ time, respectively). Conclusions: This large, prospective study supports implementation of routine height and weight collection within breast screening programs. It shows that asking women their height and weight does not deter them from returning to screening and that women with increased BMI are less likely to rescreen, highlighting a need for targeted interventions to improve screening barriers for women living with obesity.
MeSH term(s)	Humans ; Female ; Prospective Studies ; Breast/diagnostic imaging ; Breast Neoplasms/diagnosis ; Breast Neoplasms/epidemiology ; Obesity/complications ; Obesity/epidemiology ; Probability
Language	English
Publishing date	2024-01-11
Publishing country	United States
Document type	Journal Article
ZDB-ID	2659751-2
ISSN	2045-7634 ; 2045-7634
ISSN (online)	2045-7634
ISSN	2045-7634
DOI	10.1002/cam4.6883
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Increasing Inclusiveness of Patient-Centric Clinical Evidence Generation in Oncology: Real-World Data and Clinical Trials.

Benbow, Jennifer H / Rivera, Donna R / Lund, Jennifer L / Feldman, Jill E / Kim, Edward S

American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting

2021 Volume 42, Page(s) 1–11

Abstract: Rapid advancements in cancer discovery, diagnosis, and treatment options available to patients with cancer have highlighted the need for enhancements in clinical trial design. The drug development process is costly, with more than 80% of trials failing ... ...

Abstract	Rapid advancements in cancer discovery, diagnosis, and treatment options available to patients with cancer have highlighted the need for enhancements in clinical trial design. The drug development process is costly, with more than 80% of trials failing to reach recruitment targets. Historical approaches to trial design are increasingly burdensome and lack real-world application in the intent-to-treat patient population. Equitable access to clinical trials combined with increased availability of real-world data are creating new opportunities for inclusiveness, improved outcomes, and evidence-based advances in therapies that will generate more generalizable data to better inform clinical decision-making. Clinical trials need to be inclusive if lifesaving data are not to be missed and investigational therapies are to be more accessible to a broader patient base. Real-world data can facilitate the conduct of studies that are identifying and understanding where disparities exist and developing new interventions to improve patient care. The clinical trial design process should be a multistakeholder and consensus- and evidence-driven process in which stakeholders are working together across the health care industry to close the care gap and ensure elimination of barriers that prevent equal access to specialized cancer care and advanced therapies available in clinical trials. The patient voice is essential throughout the trial process; however, it is often excluded from the design process. Integrating real-world data as well as ensuring patient involvement in early trial design during drug development can enhance enrollment and retention, leading to greater diversity.
MeSH term(s)	Clinical Decision-Making ; Humans ; Medical Oncology ; Neoplasms/diagnosis ; Neoplasms/epidemiology ; Neoplasms/therapy ; Patient Participation ; Patient-Centered Care
Language	English
Publishing date	2021-09-29
Publishing country	United States
Document type	Journal Article
ZDB-ID	2431126-1
ISSN	1548-8756 ; 1548-8748
ISSN (online)	1548-8756
ISSN	1548-8748
DOI	10.1200/EDBK_350574
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Adherence to prescription proton pump inhibitor therapy amongst individuals diagnosed with Barrett's esophagus.

Gaber, Charles E / Abdelaziz, Abdullah I / Sarker, Jyotirmoy / Lund, Jennifer L / Dellon, Evan S / Cotton, Cary C / Eluri, Swathi / Shaheen, Nicholas J

Pharmacoepidemiology and drug safety

2023 Volume 33, Issue 2, Page(s) e5760

Abstract: Introduction: In the United States, clinical guidelines recommend daily use of proton pump inhibitors (PPIs) amongst individuals diagnosed with Barrett's esophagus to decrease the risk of progression to dysplasia and neoplasia. Prior studies documenting ...

Abstract	Introduction: In the United States, clinical guidelines recommend daily use of proton pump inhibitors (PPIs) amongst individuals diagnosed with Barrett's esophagus to decrease the risk of progression to dysplasia and neoplasia. Prior studies documenting adherence to PPIs in this population have not characterized heterogeneity in adherence patterns. Factors that may relate to adherence are incompletely described. Methods: We used administrative claims data from the Merative MarketScan Commercial Claims and Encounters database to conduct a retrospective study of adherence to prescription PPIs. A cohort of individuals diagnosed with incident Barrett's esophagus between 2010 and 2019 was identified. Group-based trajectory models were generated to detect longitudinal adherence subgroups. Results: 79 701 individuals with a new diagnosis of Barrett's esophagus were identified. The best fitting model detected five distinct adherence trajectory groups: consistently high (44% of the population), moderate decline (18%), slow decline (12%), rapid decline (10%), and decline-then-increase (16%). Compared to individuals starting PPIs, those already using PPIs were less likely to have a declining adherence pattern. Other factors associated with membership in a declining adherence group included (but were not limited to): female sex, having a past diagnosis of anxiety or depression, and having one or more emergency department visits in the past year. Discussion: Using an exploratory method, we detected heterogeneity in adherence to prescription PPIs. Less than half of individuals were classified into the consistently high adherence group, suggesting that many individuals with Barrett's esophagus receive inadequate pharmacologic therapy.
MeSH term(s)	Female ; Humans ; Barrett Esophagus/diagnosis ; Barrett Esophagus/drug therapy ; Barrett Esophagus/epidemiology ; Proton Pump Inhibitors/therapeutic use ; Esophageal Neoplasms/epidemiology ; Retrospective Studies
Chemical Substances	Proton Pump Inhibitors
Language	English
Publishing date	2023-10-04
Publishing country	England
Document type	Journal Article
ZDB-ID	1099748-9
ISSN	1099-1557 ; 1053-8569
ISSN (online)	1099-1557
ISSN	1053-8569
DOI	10.1002/pds.5760
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 3395: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Patterns of use of recombinant zoster vaccine among commercially-insured immunocompetent and immunocompromised adults 50-64 years old in the United States.

Fix, Jonathan / Vielot, Nadja A / Lund, Jennifer L / Weber, David J / Smith, Jennifer S / Hudgens, Michael G / Becker-Dreps, Sylvia

Vaccine

2022 Volume 41, Issue 1, Page(s) 49–60

Abstract: Purpose: The Centers for Disease Control and Prevention (CDC) recommends recombinant zoster vaccination (RZV) for adults ≥ 50 years to prevent herpes zoster (HZ) and its sequelae. Initially, no distinct recommendation was made for immunocompromised ... ...

Abstract	Purpose: The Centers for Disease Control and Prevention (CDC) recommends recombinant zoster vaccination (RZV) for adults ≥ 50 years to prevent herpes zoster (HZ) and its sequelae. Initially, no distinct recommendation was made for immunocompromised adults, who experience higher HZ rates and more severe outcomes. We characterized receipt of first RZV dose (initiation) and both doses (completion) over time, and the impact of immune function on RZV uptake among adults aged 50-64 years in the United States. Methods: We identified RZV claims from the IBM MarketScan database between 1/1/2018 and 12/31/2019. We characterized immunocompromised enrollees as having malignancy, HIV, solid organ transplant, primary immunosuppression, or medication-induced immunosuppression using inpatient, outpatient, and prescription claims in the 6 months prior to study start. We evaluated patterns of vaccine uptake by demographic and healthcare access characteristics and immune status. Results: The cumulative incidence of RZV initiation during the study period was 10.0%. Incidence increased with age and number of medical office visits, and was higher among women, urban residents, high-deductible insurance beneficiaries, and those who were immunocompromised compared to immunocompetent. Among immunocompromised adults, RZV initiation was highest among those with HIV and primary immunodeficiencies. Of those who initiated RZV, 89.5% received both doses. RZV completion was highest among those who received the first dose at a pharmacy. Most enrollees (88.6%) who completed RZV vaccination did so within the recommended dosing schedule. Conclusions: RZV uptake was low in the two years since the CDC recommendation, and differed by demographic, healthcare access, and clinical characteristics. Initiation rates were higher among immunocompromised adults compared to immunocompetent adults, despite no CDC recommendation for vaccination in these groups during the study period. The CDC has since recommended RZV for immunocompromised individuals, and our findings may inform efforts to increase RZV uptake in individuals at higher risk of severe disease.
MeSH term(s)	Adult ; Female ; Humans ; United States/epidemiology ; Middle Aged ; Herpes Zoster Vaccine ; Herpes Zoster/epidemiology ; Herpes Zoster/prevention & control ; Herpesvirus 3, Human ; Vaccines, Synthetic ; HIV Infections/complications
Chemical Substances	Herpes Zoster Vaccine ; Vaccines, Synthetic
Language	English
Publishing date	2022-11-14
Publishing country	Netherlands
Document type	Journal Article ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov't
ZDB-ID	605674-x
ISSN	1873-2518 ; 0264-410X
ISSN (online)	1873-2518
ISSN	0264-410X
DOI	10.1016/j.vaccine.2022.10.076
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 1930: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (1.OG) ab Jg. 2022: Lesesaal (EG)
Zs.MO 458: Show issues

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Unique immune profiles in collaborative cross mice linked to survival and viral clearance upon infection.

Graham, Jessica B / Swarts, Jessica L / Leist, Sarah R / Schäfer, Alexandra / Bell, Timothy A / Hock, Pablo / Farrington, Joe / Shaw, Ginger D / Ferris, Martin T / Pardo-Manuel de Villena, Fernando / Baric, Ralph S / Lund, Jennifer M

iScience

2024 Volume 27, Issue 3, Page(s) 109103

Abstract: The response to infection is generally heterogeneous and diverse, with some individuals remaining asymptomatic while others present with severe disease or a diverse range of symptoms. Here, we address the role of host genetics on immune phenotypes and ... ...

Abstract	The response to infection is generally heterogeneous and diverse, with some individuals remaining asymptomatic while others present with severe disease or a diverse range of symptoms. Here, we address the role of host genetics on immune phenotypes and clinical outcomes following viral infection by studying genetically diverse mice from the Collaborative Cross (CC), allowing for use of a small animal model with controlled genetic diversity while maintaining genetic replicates. We demonstrate variation by deeply profiling a broad range of innate and adaptive immune cell phenotypes at steady-state in 63 genetically distinct CC mouse strains and link baseline immune signatures with virologic and clinical disease outcomes following infection of mice with herpes simplex virus 2 (HSV-2) or severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). This work serves as a resource for CC strain selection based on steady-state immune phenotypes or disease presentation upon viral infection, and further, points to possible pre-infection immune correlates of survival and early viral clearance upon infection.
Language	English
Publishing date	2024-02-02
Publishing country	United States
Document type	Journal Article
ISSN	2589-0042
ISSN (online)	2589-0042
DOI	10.1016/j.isci.2024.109103
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article ; Online: Pharmacoepidemiology and Drug Safety's special issue on validation studies.

Chun, Danielle S / Lund, Jennifer L / Stürmer, Til

Pharmacoepidemiology and drug safety

2019 Volume 28, Issue 2, Page(s) 123–125

MeSH term(s)	Algorithms ; Data Interpretation, Statistical ; Databases, Factual/statistics & numerical data ; Drug-Related Side Effects and Adverse Reactions/epidemiology ; Humans ; Pharmacoepidemiology/methods ; Pharmacoepidemiology/statistics & numerical data ; Validation Studies as Topic
Language	English
Publishing date	2019-02-03
Publishing country	England
Document type	Introductory Journal Article
ZDB-ID	1099748-9
ISSN	1099-1557 ; 1053-8569
ISSN (online)	1099-1557
ISSN	1053-8569
DOI	10.1002/pds.4694
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 3395: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article: Methodological Challenges for Epidemiologic Studies of Deprescribing at the End of Life.

Tjia, Jennifer / Lund, Jennifer L / Mack, Deborah S / Mbrah, Attah / Yuan, Yiyang / Chen, Qiaoxi / Osundolire, Seun / McDermott, Cara L

Current epidemiology reports

2021 Volume 8, Issue 3, Page(s) 116–129

Abstract: ... Deprescribing includes reducing the number of medications, decreasing medication dose(s), and eliminating ...

Abstract	Purpose of review: To describe approaches to measuring deprescribing and associated outcomes in studies of patients approaching end of life (EOL). Recent findings: We reviewed studies published through 2020 that evaluated deprescribing in patients with limited life expectancy and approaching EOL. Deprescribing includes reducing the number of medications, decreasing medication dose(s), and eliminating potentially inappropriate medications. Tools such as STOPPFrail, OncPal, and the Unnecessary Drug Use Measure can facilitate deprescribing. Outcome measures vary and selection of measures should align with the operationalized deprescribing definition used by study investigators. Summary: EOL deprescribing considerations include medication appropriateness in the context of patient goals for care, expected benefit from medication given life expectancy, and heightened potential for medication-related harm as death nears. Additional data are needed on how EOL deprescribing impacts patient quality of life, caregiver burden, and out-of-pocket medication-related costs to patients and caregivers. Investigators should design deprescribing studies with this information in mind.
Language	English
Publishing date	2021-04-23
Publishing country	Switzerland
Document type	Journal Article
ISSN	2196-2995
ISSN	2196-2995
DOI	10.1007/s40471-021-00264-7
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

Order via subito

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Details ▾
- Full text online
- Order with fees

Article ; Online: Family Caregiving for Those With and Without Dementia in the Last 10 Years of Life.

Reckrey, Jennifer M / Bollens-Lund, Evan / Husain, Mohammed / Ornstein, Katherine A / Kelley, Amy S

JAMA internal medicine

2020 Volume 181, Issue 2, Page(s) 278–279

MeSH term(s)	Aged ; Caregivers ; Dementia/nursing ; Family ; Humans ; Time Factors ; United States/epidemiology
Language	English
Publishing date	2020-12-08
Publishing country	United States
Document type	Journal Article ; Research Support, N.I.H., Extramural
ZDB-ID	2699338-7
ISSN	2168-6114 ; 2168-6106
ISSN (online)	2168-6114
ISSN	2168-6106
DOI	10.1001/jamainternmed.2020.4012
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Ua VI Zs.119: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

To top

More links

Kategorien

Order via subito

Inter-library loan at ZB MED

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

Inter-library loan at ZB MED

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

Order via subito

Inter-library loan at ZB MED

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito